Depomed (DEPO) Misses Q4 EPS by 13c

Depomed (NASDAQ: DEPO) reported Q4 EPS of $0.16, $0.13 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $111.2 million versus the consensus estimate of $110.24 million.

Non-GAAP adjusted earnings includes a reduction of $10 million, or $0.13 cents per share related to the tax treatment of the cebranopadol transaction.

For earnings history and earnings-related data on Depomed (DEPO) click here.

You May Also Be Interested In

• Hertz cuts guidance, announces notes and stock offerings, shares sink
• Goldman Sachs Assumes Klaviyo Inc (KVYO) at Buy
• KB Home (KBH) PT Raised to $66 at UBS on Market Stabilisation and Execution